Azopharma’s novel approach to speeding clinical trial material into clinic is called Phase I Express™.

Q: What is Phase I Express™?

A: Phase I Express™ is a proprietary approach for expediting drug development for new compounds entering clinical development activities.

Q: How does that differentiate Azopharma from other contract research organizations?

A: Phase I Express™ differentiates Azopharma from other contract labs in several ways. Our integrated services allow us to perform numerous studies in parallel which otherwise would have been performed sequentially. This allows us to cut out unnecessary delays in your project. Additionally, our systems are optimized to promote communication between the parallel studies to insure consistency and relevance between studies. Azopharma’s integrated services also reduces the time lag of dealing with multiple vendors.

Q: Can Phase I Express™ be used with all dosage forms?

A: Phase I Express™ systems have been used successfully in all dosage forms including cytotoxic and highly potent compounds:

• Solid oral dosages (tablets, capsules)
• Liquid dosages (injectables, suspensions)
• Topical dosages (creams, ointments, lotions)
• Inhalation dosages (nasal, MDI, DPI)
• Transdermal systems

Q: What time savings could a customer expect to find with Phase I Express™ compared to industry standards for development of clinical trial materials for Phase I studies?

A: Typical industry timing to get a molecule into a Phase I clinic is around 8 to 12 months. Azopharma is able to develop clinical trial material in 6 months or less resulting in a savings of 4-6 months.